Reviewing Eton Pharmaceuticals (ETON) & Uniqure (QURE)
Eton Pharmaceuticals (NASDAQ:ETON) and Uniqure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
This is a breakdown of recent ratings and target prices for Eton Pharmaceuticals and Uniqure, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Eton Pharmaceuticals and Uniqure’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Uniqure||$13.11 million||84.97||-$79.26 million||($2.94)||-10.16|
Eton Pharmaceuticals has higher earnings, but lower revenue than Uniqure.
This table compares Eton Pharmaceuticals and Uniqure’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
60.6% of Uniqure shares are held by institutional investors. 1.6% of Uniqure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Uniqure beats Eton Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company is developing DS-300, an injectable nutrition product candidate; EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-103, an oral liquid product candidate; DS-100, an injectable product candidate for use in pain management; DS-200, an injectable parenteral nutrition product candidate; ET-101, an oral liquid product for use in seizure control; ET-102, an oral liquid product for use as a muscle relaxant; and CT-100, a synthetic corticotropin therapeutic candidate that mimics the amino acid chain of H.P. Acthar Gel. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.